ClinicalTrials.gg
TerminatedNCT00743184Updated Nov 22, 2021

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

A Phase 2 interventional study of ozarelix and Placebo in Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS), sponsored by Spectrum Pharmaceuticals, Inc. Terminated at 1 site in United States. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-11-22.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Enrollment
112th of 150
28 · median 83
Started
2008
with 8 others
Phase 2
27 of 188
3 open now
Registered
41st of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 112th largest by enrollment of the 150 interventional ones that give a count, is one of 9 that started in 2008, is one of 27 in phase 2, and was the 41st registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men as assessed by the International Prostate Symptom Score (IPSS) at Week 14.

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-controlled study.

Participants who meet the entry IPSS inclusion criteria at Week 0 will be randomized and enroll in the double-blind treatment period. Participants will be randomized to one of three treatment arms and will receive two 6-month courses of study drug administered on Days 0 and 14 of each 6-month course. Treatment arms include: ozarelix 30mg + 15mg, ozarelix 15mg + 15mg or placebo + placebo. Safety and efficacy assessments will be performed at defined intervals throughout the study. At Week 52 all participants on study will be eligible to receive ozarelix for two additional courses in the open-label treatment period.

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)
  • Lower Urinary Tract Symptoms (LUTS)

Keywords

  • BPH
  • LUTS
  • Lower urinary tract symptoms (LUTS)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has the participant given written ?
  2. Is the participant at least 50 years old?
  3. Is the participant diagnosed with BPH and has he had clinical signs and symptoms of BPH for ≥ 6 months?
  4. Does the participant have an IPSS ≥ 13?
  5. Does the participant have a peak urinary flow rate (Qmax) of 4-15 mL/sec (utilizing the 2-second rule) established on a voided volume of at least 125 mL?
  6. Does the participant have an IPSS Quality of life (QoL) score of ≥ 3?
  7. Does the participant have a PSA > 0.8 ng/mL?
  8. For participant with a PSA between 4 and 10 ng/mL or suspicion of prostate cancer, has the patient had a diagnostic evaluation (e.g., , PSA, velocity, etc.) that reasonably excludes the diagnosis of prostate cancer?
  9. Is the participant willing to agree not to use any other approved or experimental pharmacologic BPH treatments including but not limited to alpha blockers, 5-alpha reductase inhibitors, anti-cholinergic preparations or herbal preparations at any time during the study?
  10. Is the participant willing to restrict use of Phosphodiesterase 5 (PDE 5) inhibitors exclusively to the use of Viagra, one dose per week only and with no dosing in the 5 days immediately preceding scheduled study visit?
  11. Is the patient willing and able to abide by the protocol?
  12. Does the participant have an IPSS ≥ 13?
  13. Does the participant have an IPSS QoL score of ≥ 3?
  14. Does the participant have a post-void residual ≤ 350cc?

Exclusion criteria

Exclusion Criteria (all must be answered No):

  1. Does the participant have a history of prostate cancer or a serum prostate specific antigen (PSA) >10 nanogram per milliliter (ng/mL)?
  2. Has the participant had prior prostate or bladder surgery, pelvic surgery (excluding hernia repair), pelvic radiation or lower urinary tract ?
  3. Does the participant have a prevoid total bladder volume assessed by ultrasound > 550 mL?
  4. Does the participant have a post void residual urine volume ≥ 350 mL by ultrasound?
  5. Has the participant taken or is the patient currently taking any of the following:

    1. Estrogens, phytoestrogens, androgens, antiandrogens or luteinizing hormone-releasing hormone (LHRH) agonists within the past 4 months (e.g. testosterone gel [Androgel ®1%, Testim ® 1%], testosterone buccal [Striant®], oxymetholone [Anadrol®-50], oxandrolone [Oxandrin®], esterified estrogen and methyltestosterone [Estratest®]), bicalutamide [Casodex®], nilutamide [Nilandron®], flutamide [Eulexin®], leuprolide acetate [Lupron®, Eligard®, Viadur®], goserelin acetate [Zoladex®] or,
    2. 5 α-reductase inhibitors within the past 4 months (e.g. finasteride[Proscar®, Propecia®], dutasteride [Avodart®]) or,
    3. Alpha blockers or anti-cholinergic preparations within the past 6 weeks (e.g. doxazosin [Cardura®], terazosin [Hytrin®], tamsulosin [Flomax®], alfuzosin [Uroxatrol®], oxybutynin [Ditropan®], tolterodine [Detrol-LA®], amitriptyline [Elavil®, Limbitrol®]) or,
    4. Class 1A (e.g. quinidine, procainamide, disopyramide) or Class III Anti-arrhythmic (e.g.sotalol [Betapace®], amiodarone [Cordarone®])
  6. Does the participant have or has the patient ever had a diagnosis of acute or chronic prostatitis or chronic pelvic pain syndrome?
  7. Has the participant had a urinary tract infection or instrumentation (e.g catheterization, cystoscopy, prostate ) within the past 4 weeks?
  8. Does the participant have a history of urethral stricture, bladder stones, obstructing median lobe or neurogenic bladder dysfunction?
  9. Does the participant have microscopic hematuria greater than trace by dipstick urine at Visit 1?
  10. Did the participant have a positive drug screening result?
  11. Does the participant have a history of urinary retention?
  12. Does the participant have any serious medical condition (e.g., Congestive heart failure [CHF], poorly controlled diabetes ( [HgbA1c] > 9), psychiatric disorder, drug or alcohol abuse) that might interfere with his ability to comply with or complete the protocol?
  13. Is the participants interval (QTc) interval on the screening (ECG) > 450ms, or does he have a family history of long QT syndrome?
  14. Does the participant anticipate or plan to have an elective surgery or surgical procedure requiring general, spinal or epidural anesthesia during the course of the double-blind treatment portion of the study(within the next 12 months)?
  15. Has the participant ever received ozarelix, cetrorelix, teverelix or degarelix?
  16. Has the participant participated in any other study of an drug or treatment for the signs and symptoms LUTS or BPH in the past 12 months?
  17. Has the participant participated in any other clinical research study or study of an investigational drug in the past 90 days?
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Placebo

    Participants will receive Placebo + Placebo on Days 0 and 14 of each 6-month course.

    Drug: Placebo

  • Experimental
    15 mg Ozarelix + 15 mg Ozarelix

    Participants will receive 15 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.

    Drug: ozarelix

  • Experimental
    30 mg Ozarelix + 15 mg Ozarelix

    Participants will receive 30 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.

    Drug: ozarelix

Interventions

  • One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.

  • DrugPlacebo

    Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.

06

What researchers measure

Primary outcomes

  1. Change From Baseline International Prostate Symptom Score (IPSS) Score at Week 14

    IPSS is a validated self-administered index for grading benign prostatic hyperplasia (BPH)-related signs and symptoms. It consists of a set of seven questions. A total score of 1-7 indicates mild disease, 8-19 moderate disease and 20-35 severe disease.

    Time frame: Week 14

Secondary outcomes

  1. Change From Baseline IPSS (Including Sub-scores) at Week 52

    The International Prostate Symptom Score (IPSS) consists of 7 questions concerning urinary symptoms and 1 question concerning quality of life (QoL) with total score and subscores (voiding, storage and QoL). 1) Voiding- The subscale voiding score is the sum of the responses to 4 voiding symptoms questions (incomplete emptying, intermittency, weak stream, and straining). 2) Storage- The subscale storage score is the sum of the responses to 3 storage symptoms questions (frequency, urgency, and nocturia). Voiding and Storage: the lowest and highest possible scores range from 0 to 15 (mildly symptomatic to severely symptomatic). Voiding and Storage: each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. And 3) QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The lowest and highest possible score ranges from 0 to 6 (very pleased to terrible).

    Time frame: Week 52

  2. Change From Baseline Benign Prostatic Hyperplasia Impact Index (BPHII) Score at Week 14 and Week 52

    BPH Impact Index (BII) is used to assess the impact of BPH on various aspects of health. This 4 question self administered index uses a scoring range from 0 (best) to 13 (worst).

    Time frame: Weeks 14 and 52

  3. Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ) Response at Week 52

    The self administered LUTS GAQ is a "yes" or "no" response to a question asking whether overall improvement in LUTS will be observed during the treatment period.

    Time frame: Week 52

  4. Change From Baseline Maximum Urine Flow (Qmax) at Week 14 and Week 52

    Qmax was measured by free flow uroflowmetry. Qmax is defined as the peak urine flow rate (measured in milliliter (mL)/second using a standard calibrated flowmeter). For a Qmax to be considered valid, the voided volume had to be at least 125 mL. The uroflowmeter is to be calibrated weekly.

    Time frame: Week 14 and Week 52

  5. Change From Baseline International Index of Erectile Function-15 (IIEF-EF) Score at Week 14 and Week 52

    IIEF-EF is defined as the sum of the scores for Questions 1-5 and 15 of the IIEF questionnaire. This recall instrument is self-administered by the participant. Individual questions are graded from 1 to 5 with a maximum total score of 30. Lower IIEFEF scores represent diminished erectile function. Men with a score of ≥ 26 are interpreted as having normal erectile function.

    Time frame: Week 14 and Week 52

  6. Change From Baseline International Prostate Symptom Score - Quality of Life (IPSS-QOL) at Week 14 and Week 52

    IPSS QOL is a disease-specific quality of life question, referred to as IPSS Question 8. Participants with an IPSS QOL of \<3 at screening will be excluded from this study. The rating is as follows: 0=delighted, 1=pleased, 2=mostly satisfied, 3=mixed, 4=mostly dissatisfied, 5=unhappy, 6=terrible.

    Time frame: Week 14 and Week 52

  7. Number of Participants With Treatment-Emergent Adverse Events

    Time frame: Up to 104 weeks

07

Study locations

1 site
  • California Professional Research
    Newport Beach, California 92660, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2008 to primary completion in Jan 2010, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2008
First posted
Aug 28, 2008
StartActual
Dec 4, 2008
Primary completionActual
Jan 20, 2010
CompletionActual
Jan 20, 2010
Results delay requested
Oct 28, 2021
Last update
Nov 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00743184
Responsible party
Sponsor
First posted
Aug 28, 2008
Start date
Dec 4, 2008
Primary completion
Jan 20, 2010
Completion
Jan 20, 2010
Last update
Nov 22, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozarelix

Start the discussion